LifeSci Acquisition II Corp.
Status: Deal Closed
U=S
| IPO Proceeds, $M | $80.09M |
|---|---|
| IPO Date | Nov 20, 2020 |
| CEO | Andrew McDonald, Ph.D. |
| Left Lead | LifeSci Capital |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Healthcare in North America |
| IPO Geography | US/Canada |
| Target Company | Science 37 |
| Deal Announced | May 7, 2021 |
| Deal Size, $M | $1,050.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 4, 2021 |
| Amendment Vote | TBD |
| Closing Date | Oct 7, 2021 |
Formerly LSAQ
SNCE
| Price | 5.75 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on LifeSci Acquisition II Corp.:
- Structure and cap table
- 8 directors & officers
- 19 filings and events
- 2 underwriters
- 6 deal advisors
- 3 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Andrew McDonald, Ph.D. | 46 | Chairman, CEO and Director |
| Michael Rice | 55 | COO and Director |
| David Dobkin | 41 | CFO and Director |
| Thomas Wynn | 51 | Director |
| Thomas Mathers | 53 | Director |
| Elizabeth Barrett | 58 | Director |
| Graham Walmsley | 33 | Director |
| Scott Janssen | 51 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| LifeSci Capital | Joint BR | 5,625,000 | units |
| Ladenburg Thalmann | Joint BR | 1,875,000 | |
| 7,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| BCMA | 3.28 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.